The application of Beckman Coulter VCS technology at major cancer center, with emphasis on the detection of circulating immature plasma cells in plasma cell leukemia

Laboratory Hematology

Volumn 12, Issue 4, 2006, Pages 210-216

  Marionneaux, Steven ^a   Monsalve, B ^a   Plante, N ^a   Shulman, S ^a   Vega, A M ^a  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Beckman Coulter GenS; Beckman Coulter LH 750; Plasma cells; Scatterplots; VCS

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; THALIDOMIDE;

ADULT; ANALYZER; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER CENTER; CANCER CYTODIAGNOSIS; CANCER SURVIVAL; CASE REPORT; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY AUTOMATION; LABORATORY TEST; LEUKOCYTE DIFFERENTIAL COUNT; LIGHT SCATTERING; MALE; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; PATHOLOGICAL ANATOMY; PATIENT MONITORING; PLASMA CELL; PLASMA CELL LEUKEMIA; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

AUTOANALYSIS; DATA DISPLAY; EQUIPMENT AND SUPPLIES; FEMALE; FLOW CYTOMETRY; HUMANS; LABORATORIES, HOSPITAL; LEUKEMIA, PLASMACYTIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 34848866682     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.06034     Document Type: Article

References (11)

1. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma [review]. Hematol Oncol Clin North Am. 1997;11:27-42.
2. Ahsmann EJ, Lokhorst HM, Dekker AW, Bloem AC. Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood. 1992;79:2068-2075.
3. Masellis-Smith A, Belch AR, Mant MJ, Turley EA, Pilarski LM. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood. 1996;87:1891-1899.
4. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993;81:767-774.
5. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987;83:1062-1068.
6. Fritz E, Ludwig H, Kundi M. Prognostic relevance of cellular morphology in multiple myeloma. Blood 1984;63:1072-1079.
7. Carter A, Hocherman I, Linn S, Cohen Y, Tatarsky I. Prognostic significance of plasma cell morphology in multiple myeloma. Cancer. 1987;60:1060-1065.
8. Pasqualetti P, Casale R, Collacciani A, Abruzzo BP, Colantonio D. Multiple myeloma: relationship between survival and cellular morphology. Am J Hematol. 1990;33:145-147.
9. Goasguen JE, Zandecki M, Mathiot C, et al. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res. 1999;23:1133-1140.
10. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998;91:2501-2507.
11. Junior EC, Reis AB, Silva C, Fernandes IB, Simon R. Localization of the plasmacytic population in the cell counter of the Coulter MAXM scatterplots: a case of plasma cell leukemia. Lab Hematol. 1997;3:1-2.